Find Locations
For hours, walk-ins and appointments.Synonyms
- Anti-HBe
- Antibody to Hepatitis Be Antigen
- HBeAb
Expected Turnaround Time
1 - 5 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
Volume
0.5 mL
Minimum Volume
0.2 mL (Note: This volume does not allow for repeat testing.)
Container
Serum gel tube, serum transfer tube, red-top tube, lavender-top (EDTA) tube, plasma transfer tube
Collection
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube.
Storage Instructions
Room temperature
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 7 days (stability provided by manufacturer or literature reference) |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Causes for Rejection
Gross hemolysis or visible bacterial contamination
Test Details
Use
The presence of antibody to hepatitis Be antigen (anti-HBe) can be used in conjunction with other serological and clinical information to determine the stage and prognosis of hepatitis B infection.
Methodology
Competitive chemilumescence immunoassay (CLIA)
Reference Interval
Negative
Additional Information
The appearance of anti-HBe in patients who have previously been HBeAg positive indicates a reduced risk of infectivity. Failure of appearance implies disease activity and probable chronicity but patients with HBeAb may have chronic hepatitis. Chronic HBsAg carriers can be positive for either HBeAg or anti-HBe, but are less infectious when anti-HBe is present. HBe can persist for years, but usually disappears earlier than anti-HBs or anti-HBc. Anti-HBe has not been found as the sole serologic marker for hepatitis B infection.
References
Abara WE, Qaseem A, Schillie S, et al. Hepatitis B Vaccination, Screening, and Likage to Care: Best Practice Advice from American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.29159414
Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018 Jan 12;67(1):1-31.29939980
Terrault NA, Lok ASF, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018 Apr;67(4):1560-1599.29405329
Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.26042815
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 006635 | Hep Be Ab | 13953-5 | 006635 | Hep Be Ab | 13953-5 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf